ACIU · AC Immune S.A.

AC Immune SA announced the retirement of its co-founder and CEO, Dr. Andrea Pfeifer, after a 23-year tenure. Dr. Pfeifer will step down at the upcoming Annual General Meeting, with Board Chair Dr. Martin Zügel appointed as interim CEO. Dr. Pfeifer will remain as an Advisor, Honorary Chair of the Board, and Co-Chair of the Scientific Advisory Board to facilitate the transition. The company has initiated a CEO search with a leading industry consultant. This leadership change comes at a time when AC Immune is well-positioned with a robust balance sheet, three Precision Prevention candidates in the clinic for Alzheimer's and Parkinson's, and strategic partnerships with Eli Lilly, Takeda, and Johnson & Johnson. The company expects multiple near-term value-inflection milestones. Dr. Zügel brings extensive experience, having previously served as CEO of Merz Pharma and played a key role in building memantine into a blockbuster Alzheimer's drug. The transition is designed to ensure continuity and leverage Dr. Pfeifer's ongoing advisory role.